Navigation Links
Blood sugar improves with first gastrointestinal microbiome modulator, NM504
Date:6/23/2014

CHICAGO, IL In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerancethe body's response to consuming carbohydrates after four weeks of treatment and without a change in diet. These results, from a pilot study, will be presented Monday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

The not-yet-named therapeutic, NM504, is the first in a new class of therapies known as GI microbiome modulators. The GI microbiomethe mix of microbial and associated physical and chemical factors in the digestive systemmay play a critical part in regulating the body's metabolism, some researchers believe. There is recent scientific evidence that microbial imbalance, or dysbiosis, in the gut contributes to the development of Type 2 diabetes.

"We believe that modern Western diets contribute to development of Type 2 diabetes, in part because they change the habitat of the microorganisms that reside in the gut. This shifts the microbial populations that live there in ways that affect metabolic health," said Mark Heiman, PhD, the study's principal investigator. Heiman is chief scientific officer for MicroBiome Therapeutics, the Colorado-based biotechnology company that is developing NM504 and sponsored the study.

NM504 is designed to shift the GI bacteria and other microorganismscalled microbiotaand their environment in specific ways to achieve improved health outcomes, according to Heiman. He said the drug contains concentrated bioactive food ingredients: inulin, a fiber; beta-glucan and polyphenolic antioxidant compounds.

Heiman and colleagues conducted a study in 28 adults with prediabetes, a frequent precursor to Type 2 diabetes. Fourteen subjects were randomly assigned to receive NM504 twice a day, and the other 14 were assigned to receive placebo, or "dummy" material. Neither the subjects nor the investigators were aware of the drug assignments. Before any treatment and again at four weeks of treatment, all subjects had an oral glucose challenge. In this test, they drank a concentrated glucose (sugary) drink and then had their blood sugar levels tested at various times and compared with pretest levels.

Blood sugar levels at 120 and 180 minutes after the glucose challenge were significantly lower in subjects who took NM504 than those who received the placebo, Heiman reported. Also during this test, NM504 increased insulin sensitivity, the body's ability to successfully clear glucose from the bloodstream.

Compared with placebo, NM504 treatment also decreased the desire to eat, which Heiman said Microbiome Therapeutics' researchers had hoped the therapeutic would do. He said the subjects tolerated NM504 well, with only a mild increase in flatulence, or gas.

"This work indicates a new therapeutic targetthe GI microbiomethat has the potential to revolutionize the treatment of metabolic diseases such as Type 2 diabetes," Heiman commented.

MicroBiome Therapeutics reports that the company plans to develop NM504 and/or a closely related therapeutic as a prescription medicine to treat prediabetes and diabetes.


'/>"/>
Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Halo Labs announces the European launch of ... the HORIZON at MIBio 2017 in Cambridge, U.K ... particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity while ... technique Backgrounded Membrane Imaging. ... HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
Breaking Medicine Technology: